# Benitec Biopharma Inc. (BNTC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.68, market value $436 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Benitec Biopharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -39.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -21.8%**. Each dollar of assets produces -21.8% of profit.

## Growth
- **EPS growth (1 yr): 13.9%**. Earnings per share rose 13.9%.

## Financial health
- **Current ratio: 54.67** (quick 54.67). Current assets cover the next year's liabilities 54.67 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Benitec Biopharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Benitec Biopharma Inc.; the consensus is strong_buy, with an average price target of $24.17 (+91% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -9.4%** (YTD -5.9%, 3-mo 20.2%). The shares are down 9.4% over twelve months including dividends.
- **From 52-week high: -24.3%** (28.7% above the low). Trading 24% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.36** (volatility 58%). Beta of 1.36 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BNTC · Page: https://foliofundamentals.com/stocks/bntc

Not investment advice.